Powered By
ANTIBODY-DRUG CONJUGATE
Datroway (datopotamab deruxtecan-dlnk) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat adults with breast cancer.
Datroway is a type of targeted cancer medicine called an antibody-drug conjugate. It attaches to Trop-2, a protein found on some cancer cells. Once attached, Datroway can enter the cell and release a medicine called DXd.
DXd can damage DNA and lead to cell death. In breast cancer, this may help slow cancer growth and destroy cancer cells.
Doctors prescribe Datroway when certain adults have advanced breast cancer, depending on the subtype and the treatments they have already received. Datroway may be used for:
Datroway is given as an intravenous (IV) infusion once every three weeks in a 21-day cycle. Treatment usually continues until the cancer gets worse or side effects become unacceptable.
The recommended dose of Datroway for breast cancer is 6 milligrams per kilogram of body weight. The maximum dose is 540 milligrams for people who weigh 90 kilograms or more. The dose is given once every three weeks.
Doctors may pause treatment, lower the dose, delay the next dose, slow the infusion, or stop treatment if side effects are serious or hard to manage.
Before and during treatment, doctors may use medicines or care steps to help lower the risk of side effects. These include lubricating eye drops, a steroid-containing mouthwash, an antihistamine, a fever-reducing medicine, and medicine to help prevent nausea and vomiting.
This information is based on the prescribing information, but your healthcare provider may tailor your treatment plan. Always follow their guidance.
In clinical studies of adults with unresectable or metastatic breast cancer, the most common side effects occurred in at least 20 percent of people taking Datroway.
For unresectable or metastatic TNBC, these side effects include:
For unresectable or metastatic HR-positive, HER2-negative breast cancer, these side effects include:
Datroway can cause serious side effects that may require immediate medical attention. These include:
Get medical help right away if you think you are having a serious reaction.
Daiichi Sankyo, the manufacturer of Datroway, offers the Datroway Patient Savings Program through Datroway4U. Eligible people with commercial insurance may pay as little as $0 per infusion.
Datroway4U also provides information about other financial assistance options that may be available to people with government insurance or no insurance. Datroway4U offers benefits reviews, assistance with prior authorizations, and support with claims appeals.
To learn more, visit the Datroway4U website or call 855-328-7648.
Before starting Datroway, your doctor will:
Tell your doctor about all medicines you take, including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements.
Before receiving Datroway, tell your healthcare provider about all your medical conditions, including if you:
Datroway is also FDA-approved to treat certain adults with non-small cell lung cancer (NSCLC).
If you miss a planned dose of Datroway, call your healthcare provider right away to schedule an appointment. Do not wait until your next planned treatment cycle.
Datroway may also cause fertility problems in males and females. This may affect the ability to have children.
Datroway can harm your baby if you are pregnant. Females who can become pregnant should use effective birth control during treatment and for seven months after the last dose.
Males with female partners who can become pregnant should use effective birth control during treatment and for four months after the last dose.
Do not breastfeed during treatment with Datroway and for one month after the last dose.
These answers are fact-checked by our editorial staff.
How effective is Datroway in breast cancer?
In one study of people with unresectable or metastatic TNBC, progression-free survival (the length of time people lived without their cancer getting worse) was 10.8 months with Datroway and 5.6 months with chemotherapy.
In the same study, overall survival (the length of time people lived after starting treatment) was 23.7 months with Datroway and 18.7 months with chemotherapy. Among participants with measurable disease, 64 percent of those who received Datroway had confirmed tumor shrinkage, compared with 30 percent of those who received chemotherapy.
In one study of people with unresectable or metastatic HR-positive, HER2-negative breast cancer, progression-free survival was 6.9 months with Datroway and 4.9 months with chemotherapy. In that study, 36 percent of people who received Datroway had confirmed tumor shrinkage, compared with 23 percent of people who received chemotherapy.
What tests or monitoring are needed with Datroway for breast cancer?
Eye monitoring is required with Datroway. You will have an eye exam when you start treatment, at the end of treatment, and as needed. During treatment, you will also have vision testing and a slit lamp exam every three cycles, or about every nine weeks.
Your care team will also watch for new or worsening breathing symptoms, such as cough, shortness of breath, fever, chest tightness, or wheezing. Datroway can cause serious lung problems.
Tell your healthcare provider right away if you have any new or worsening breathing symptoms.
On MyBCTeam, people share their experiences with breast cancer, get advice, and find support from others who understand.
Learn more about Datroway and breast cancer care:
More resources from MyBCTeam that mention Datroway
Become a member to get even more
Join
Your Privacy Choices
